A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
{{output}}
The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment c... ...
